Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

NCT01506596 is registered in ClinicalTrials.gov with Vector Oncology as lead sponsor.

NCT NCT01506596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01506596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
Lead sponsor
Vector Oncology
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2012
Completion date
March 31, 2016
Enrollment
42 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

liposarcoma, metastatic liposarcoma, surgically unresectable liposarcoma